Could aging be treated like a disease, diagnosed and reversed at the cellular level? That question has moved from speculative biotech to a funded clinical program with a date attached.
• NewLimit raised $435M in Series C at $3.1B valuation, led by Founders Fund, to take epigenetic reprogramming into first human clinical trials in 2027
• The company discovered a liver-cell reprogramming candidate that reverses cellular age markers in preclinical models — years ahead of its own projected timeline
• Eli Lilly Ventures joining the cap table signals that pharmaceutical capital now treats biological aging as a clinical category, not a wellness concept
On June 2, NewLimit, a South San Francisco company founded in 2021, closed a $435 million Series C at a $3.1 billion valuation. The round was led by Founders Fund, with new investors Thrive Capital, Greenoaks, and Quiet Capital joining returning backers Kleiner Perkins, Eli Lilly Ventures, and Valor Equity Partners. Total capital raised: more than $610 million in under 12 months.
The money pays for a specific milestone: the first clinical trial of an epigenetic reprogramming therapy in humans, scheduled for 2027.
From seed to clinic in three years
The company began with $110 million from Coinbase CEO Brian Armstrong, who co-founded it alongside bioengineer Blake Byers and computational biologist Jacob Kimmel, now its CEO. At that point, cellular reprogramming was a Nobel-winning laboratory technique (Shinya Yamanaka, 2012) with no clear clinical pathway. The bet was that it could be turned into a medicine.
In 2023, a $40 million Series A from Dimension Capital, Founders Fund, and Kleiner Perkins funded the build of an AI-driven screening platform. The system tested thousands of transcription factor combinations — proteins that switch genes on and off, looking for sets that restored youthful gene expression patterns without fully reverting cells to stem cells.
By May 2025, the company had a lead candidate and closed a $130 million Series B led by Kleiner Perkins. Kimmel told FierceBiotech at the time that a first human trial might not happen until 2030.
Then the data changed the timeline.
"Their liver reprogramming therapy allows livers to heal faster after injury, avoid damage from dietary challenges, and accelerate recovery from alcohol consumption," Kimmel wrote in the Series C announcement. "Our trial next year will reveal how liver age reprogramming translates into humans for the first time."
What epigenetic reprogramming actually does
Every cell in the human body carries the same DNA. What makes a liver cell different from a neuron is which genes are switched on or off — a regulatory layer called the epigenome. As cells age, these epigenetic marks degrade. Genes that should be active get silenced. Repair mechanisms stall. The cell becomes less functional.
Reprogramming resets those marks. The approach uses lipid nanoparticles (LNPs) to deliver mRNA encoding fewer than 10 transcription factors directly into liver cells. The mRNA is transient. It degrades after doing its job, which the company believes reduces the safety concerns that have shadowed full cellular reprogramming since the early induced-pluripotent-stem-cell era.
In preclinical models, treated old mouse livers regenerated at speeds comparable to young animals. Alcohol tolerance improved. The cells looked younger by multiple molecular clocks.
A sector finding its footing
The company operates alongside a growing cohort of billionaire-backed longevity ventures. Altos Labs, funded by Jeff Bezos and Yuri Milner, pursues iPSC-based reprogramming with a reported $3 billion in funding but no disclosed clinical timeline. Retro Biosciences, backed by Sam Altman, is working on autophagy and plasma-inspired therapies. Google's Calico has been notably quiet since the departure of several senior scientists.
What sets it apart is the speed of its transition from research to clinical development. Altos Labs has been operating since 2021 with substantially more capital and has not announced a trial date.
Eli Lilly Ventures' participation in the Series C is the strongest signal yet that pharmaceutical capital is shifting. Aging biology has long been dismissed as too speculative for late-stage investment. Lilly's presence suggests that view is changing — and that the first company to generate human data may define the commercial landscape for a generation.
The liver as a proving ground
Its decision to start with the liver is strategically conservative. The liver is one of the few organs with demonstrable regenerative capacity in humans. It can be biopsied and monitored serially. Age-related liver decline — fibrosis, metabolic dysfunction, reduced detoxification — is well-characterized clinically.
The initial Phase 1 trial targets patients with fatty liver disease, with a Phase 2 program planned for alcohol-related liver disease. Kimmel described the liver as "a central node in metabolism," noting that roughly half of adults over 60 develop metabolic syndrome — and that liver age plays a meaningful role in that process.
What success would mean
If Phase 1 data shows that epigenetic reprogramming works safely in humans, the implications extend far beyond liver disease. The company already has preclinical programs targeting endothelial cells for chronic kidney disease and T cells for autoimmune conditions. The platform is designed to be tissue-agnostic: find the right transcription factor combination for any cell type, package it in an LNP, and test.
A positive readout would also validate the entire longevity biotech thesis for institutional investors who have watched from the sidelines. The sector has attracted billions in venture funding since 2021, but no company has yet generated the kind of clinical data that justifies those valuations. NewLimit's $3.1 billion pre-revenue valuation will be measured against that data.
No pressure. Just the next three years.
• NewLimit's IND filing and FDA clearance timeline for the liver program
• Enrollment rate for the Phase 1 fatty liver disease trial — speed of recruitment signals physician conviction
• Competing timelines from Altos Labs and Retro Biosciences — any announced trial dates would reshape the field
• Lilly Ventures' follow-on behavior — a Series D participation would confirm internal conviction
• Safety signal at any dose level in the Phase 1 readout — the field's single biggest risk